CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
23andme Holding Co  (ME)
Other Ticker:  
 

23andme Holding Co's Working Capital Ratio

ME's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 2.15 below 23andme Holding Co average.

Within Major Pharmaceutical Preparations industry 212 other companies have achieved higher Working Capital Ratio than 23andme Holding Co in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 1506, from total ranking in the second quarter 2023 at 1676.

Explain Working Capital Ratio
How much in Current Assets ME´s has?
What is the value of ME´s Current Liabilities?


ME Working Capital Ratio (Dec 31 2023)
III. Quarter		 (Sep 30 2023)
II. Quarter		 (Jun 30 2023)
I. Quarter		 (Mar 31 2023)
IV. Quarter		 (Dec 31 2022)
III. Quarter
Y / Y Current Liabilities Change -27.97 % -29.88 % -6.96 % -2.5 % 11.45 %
Y / Y Current Assets Change -39.06 % -41.13 % -30.69 % -29.38 % -24.06 %
Working Capital Ratio MRQ 2.15 2.93 3.03 2.84 2.54
ME's Total Ranking # 1506 # 1676 # 1735 # 1920 # 2250
Seq. Current Liabilities Change 41.87 % -14.56 % -20.42 % -25.33 % 38.1 %
Seq. Current Assets Change 4.01 % -17.29 % -15.23 % -16.45 % 0.49 %

New: More ME's historic Working Capital Ratios >>


Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 213
Healthcare Sector # 433
Overall Market # 1506


Working Capital Ratio Statistics
High Average Low
6.77 3.51 0.02
(Sep 30 2021)   (Mar 31 2021)




Financial Statements
23andme Holding Co's Current Liabilities $ 144 Millions Visit ME's Balance sheet
23andme Holding Co's Current Assets $ 310 Millions Visit ME's Balance sheet
Source of ME's Sales Visit ME's Sales by Geography


Cumulative 23andme Holding Co's Working Capital Ratio

ME's Working Capital Ratio for the trailling 12 Months

ME Working Capital Ratio

 (Dec 31 2023)
III. Quarter		 (Sep 30 2023)
II. Quarter		 (Jun 30 2023)
I. Quarter		 (Mar 31 2023)
IV. Quarter		 (Dec 31 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -27.97 % -29.88 % -6.96 % -2.5 % 11.45 %
Y / Y Current Assets TTM Growth -39.06 % -41.13 % -30.69 % -29.38 % -24.06 %
Working Capital Ratio TTM 2.71 2.79 2.93 3.15 3.41
Total Ranking TTM # 1178 # 3574 # 1237 # 3777 # 3945
Seq. Current Liabilities TTM Growth 41.87 % -14.56 % -20.42 % -25.33 % 38.1 %
Seq. Current Assets TTM Growth 4.01 % -17.29 % -15.23 % -16.45 % 0.49 %

Working Capital ratio ranking by company, industry and sector >> Back to ME Financial Strength Comparisons >> Go to Compare ME Working Capital to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ME's Current Liabilities to $144.14 millions, cumulative Working Capital Ratio to 2.71 below the ME average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 208 other companies have achieved higher Working Capital Ratio than 23andme Holding Co. While Working Capital Ratio overall ranking has improved so far to 1178, from total ranking during the twelve months ending second quarter 2023 at 3574.

Explain Working Capital Ratio
How much in Current Assets ME´s has?
What is the value of ME´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 209
Healthcare Sector # 417
Within the Market # 1178


trailing twelve months Working Capital Ratio Statistics
High Average Low
5.02 3.66 2.71
(Mar 31 2022)   (Dec 31 2023)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Ionis Pharmaceuticals Inc  5.90 $ 2,641.853  Millions$ 448.090  Millions
Phio Pharmaceuticals Corp   5.83 $ 9.322  Millions$ 1.599  Millions
Leap Therapeutics inc   5.76 $ 71.597  Millions$ 12.422  Millions
Lexicon Pharmaceuticals Inc   5.60 $ 176.547  Millions$ 31.546  Millions
Nanoviricides inc   5.59 $ 5.318  Millions$ 0.951  Millions
Marker Therapeutics inc   5.57 $ 17.127  Millions$ 3.075  Millions
Aurinia Pharmaceuticals Inc   5.50 $ 424.800  Millions$ 77.188  Millions
Verastem inc   5.45 $ 143.682  Millions$ 26.380  Millions
Urogen Pharma Ltd   5.42 $ 169.186  Millions$ 31.212  Millions
Intra cellular Therapies Inc   5.41 $ 667.799  Millions$ 123.545  Millions
Madrigal Pharmaceuticals Inc   5.40 $ 637.281  Millions$ 118.021  Millions
Praxis Precision Medicines Inc   5.39 $ 84.880  Millions$ 15.749  Millions
Shuttle Pharmaceuticals Holdings Inc   5.37 $ 5.593  Millions$ 1.042  Millions
Pulmatrix Inc   5.33 $ 20.843  Millions$ 3.909  Millions
Immix Biopharma Inc   5.32 $ 19.788  Millions$ 3.722  Millions
Indaptus Therapeutics Inc   5.24 $ 13.995  Millions$ 2.672  Millions
Phibro Animal Health Corporation  5.22 $ 586.586  Millions$ 112.455  Millions
Legend Biotech Corporation  5.19 $ 1,497.799  Millions$ 288.531  Millions
Adc Therapeutics Sa  5.08 $ 336.291  Millions$ 66.203  Millions
Citius Pharmaceuticals Inc   5.06 $ 28.248  Millions$ 5.579  Millions
Carisma Therapeutics Inc   5.06 $ 80.471  Millions$ 15.908  Millions
Connect Biopharma Holdings Limited  4.99 $ 120.971  Millions$ 24.264  Millions
Arvinas Inc   4.98 $ 1,280.200  Millions$ 257.100  Millions
Gain Therapeutics inc  4.94 $ 17.779  Millions$ 3.598  Millions
Ardelyx Inc   4.88 $ 246.111  Millions$ 50.393  Millions
Liquidia Corporation  4.85 $ 89.899  Millions$ 18.550  Millions
Aadi Bioscience Inc   4.72 $ 124.586  Millions$ 26.395  Millions
Trevena Inc  4.66 $ 35.205  Millions$ 7.554  Millions
Zai Lab Limited  4.63 $ 939.606  Millions$ 203.067  Millions
United Therapeutics Corporation  4.62 $ 3,551.000  Millions$ 769.000  Millions

Date modified: 2024-02-08T08:16:07+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com